X
[{"orgOrder":0,"company":"HepaRegeniX","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$12.2 million","upfrontCash":"Undisclosed","newsHeadline":"Boehringer, Novo-backed German biotech banks \u20ac11M in liver regeneration push","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"HepaRegeniX"}]
Find Novel Drugs for Hepatology (Liver, Pancreatic, Gall Bladder) under Development in GERMANY
Filters
Details:
The proceeds will be used to advance the first MKK4 inhibitor for treatment of acute and chronic liver diseases to the clinics later in 2020.
Lead Product(s):
Undisclosed
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)
Product Name: Undisclosed
Highest Development Status: Undisclosed
Product Type: Undisclosed
Partner/Sponsor/Collaborator:
Boehringer Ingelheim GmbH
Deal Size: $12.2 million
Upfront Cash: Undisclosed
Deal Type: Series B Financing
January 21, 2020